Janney Montgomery Scott LLC Buys 3,468 Shares of DaVita Inc. (NYSE:DVA)

Janney Montgomery Scott LLC lifted its stake in shares of DaVita Inc. (NYSE:DVA) by 16.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,591 shares of the company’s stock after purchasing an additional 3,468 shares during the quarter. Janney Montgomery Scott LLC’s holdings in DaVita were worth $4,031,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DVA. Blue Trust Inc. grew its stake in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares in the last quarter. Family Firm Inc. bought a new stake in shares of DaVita during the 2nd quarter worth approximately $43,000. Versant Capital Management Inc boosted its position in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Friedenthal Financial bought a new position in DaVita in the second quarter valued at approximately $48,000. Finally, Point72 Hong Kong Ltd acquired a new position in DaVita during the second quarter valued at approximately $68,000. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the sale, the chief operating officer now owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock valued at $27,387,069 in the last three months. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

DVA has been the topic of several recent analyst reports. Bank of America lifted their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays increased their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $161.80.

DaVita Stock Performance

DaVita stock opened at $149.66 on Friday. The business has a 50 day moving average of $157.15 and a 200-day moving average of $146.80. The company has a market capitalization of $12.27 billion, a P/E ratio of 16.14, a P/E/G ratio of 0.83 and a beta of 0.89. DaVita Inc. has a 1 year low of $82.79 and a 1 year high of $168.50. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the business posted $2.85 EPS. DaVita’s revenue was up 4.6% on a year-over-year basis. On average, equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.